{
  "docId": "019de070-699f-77f8-bbbb-b770da56fde3",
  "docSlug": "068a25e0403b2abb3acbdc102f073cd6",
  "documentTitle": "BioNTech | Results Presentation Deck | 25 slides",
  "authorId": "biontech",
  "authorName": "BioNTech",
  "documentKindSlug": "deck",
  "documentKindLabel": "Deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2020-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 16,
  "pageCount": 25,
  "prevPage": 15,
  "nextPage": 17,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 14,
  "notes": "Data presented in a table format showing age, gender, cancer type, and prior treatment history.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-699f-77f8-bbbb-b770da56fde3/16",
  "deckHref": "/decks/019de070-699f-77f8-bbbb-b770da56fde3",
  "deckJsonHref": "/decks/019de070-699f-77f8-bbbb-b770da56fde3.json",
  "deckAnchorHref": "/decks/019de070-699f-77f8-bbbb-b770da56fde3#slide-16",
  "components": [
    {
      "bbox": {
        "h": 0.2,
        "w": 0.4,
        "x": 0.55,
        "y": 0.28
      },
      "kind": "list",
      "text": "A total of 61 patients were enrolled in the dose escalation part of the trial. Patients were heavily pretreated, receiving a median (range) of 3 (1–11) treatments; nearly 40% had received prior PD-(L)1 treatment",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1af5fafe-f9ed-43b3-9827-019a70bd1cd8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.5,
        "x": 0.04,
        "y": 0.228
      },
      "kind": "table",
      "text": "Dose Escalation Cohort, All patients N=61, Median age, years (range) 59 (23, 79), Age group, n (%) <65 years 44 (72.1), ≥65 years 17 (27.9), Female, n (%) 28 (45.9), Cancer type, a n (%) Colorectal cancer 12 (19.7), Ovarian cancer 9 (14.8), Pancreatic cancer 6 (9.8), NSCLC 6 (9.8), Other 28 (45.9), Median number of prior regimens, (range) 3 (1–11), Prior treatment with PD-(L)1 inhibitor, n (%) 23 (37.7)",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "25a6fd43-670f-4978-9e38-d382d4affd5b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.7,
        "x": 0.04,
        "y": 0.08
      },
      "kind": "title",
      "text": "BNT311: Phase 1 / 2a - Dose Escalation Patient Demographics",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "895d3918-43db-4605-9267-659e88afd6f2",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 20,
      "from": 7,
      "beatId": "7852d973-8bf2-4ccc-98c8-69a7695d2975",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "BNT162b2 Phase 3 trial, oncology pipeline, and BNT311 safety trial",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}